RS64258B1 - Heteroarilfenoksi benzamid ligandi kapa opioida - Google Patents
Heteroarilfenoksi benzamid ligandi kapa opioidaInfo
- Publication number
- RS64258B1 RS64258B1 RS20230453A RSP20230453A RS64258B1 RS 64258 B1 RS64258 B1 RS 64258B1 RS 20230453 A RS20230453 A RS 20230453A RS P20230453 A RSP20230453 A RS P20230453A RS 64258 B1 RS64258 B1 RS 64258B1
- Authority
- RS
- Serbia
- Prior art keywords
- methyl
- pyrazol
- phenoxy
- pyrrolidin
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426980P | 2016-11-28 | 2016-11-28 | |
| US201762576435P | 2017-10-24 | 2017-10-24 | |
| US201762585016P | 2017-11-13 | 2017-11-13 | |
| EP17818281.2A EP3544972B8 (en) | 2016-11-28 | 2017-11-27 | Heteroarylphenoxy benzamide kappa opioid ligands |
| PCT/IB2017/057418 WO2018096510A1 (en) | 2016-11-28 | 2017-11-27 | Heteroarylphenoxy benzamide kappa opioid ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64258B1 true RS64258B1 (sr) | 2023-07-31 |
Family
ID=60782279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20230453A RS64258B1 (sr) | 2016-11-28 | 2017-11-27 | Heteroarilfenoksi benzamid ligandi kapa opioida |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10316021B2 (enExample) |
| EP (1) | EP3544972B8 (enExample) |
| JP (1) | JP7051853B2 (enExample) |
| CN (1) | CN110234638B (enExample) |
| AU (1) | AU2017365123B2 (enExample) |
| DK (1) | DK3544972T3 (enExample) |
| ES (1) | ES2947293T3 (enExample) |
| FI (1) | FI3544972T3 (enExample) |
| HR (1) | HRP20230518T1 (enExample) |
| HU (1) | HUE061945T2 (enExample) |
| IL (1) | IL266962B (enExample) |
| MX (1) | MX389806B (enExample) |
| PH (1) | PH12019501172A1 (enExample) |
| PL (1) | PL3544972T3 (enExample) |
| PT (1) | PT3544972T (enExample) |
| RS (1) | RS64258B1 (enExample) |
| TW (1) | TWI720272B (enExample) |
| WO (1) | WO2018096510A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
| AU2018223177B2 (en) * | 2017-02-24 | 2024-05-02 | Xeniopro GmbH | Aromatic compounds which enhance notch signaling, for use in therapy |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| MX2021013934A (es) * | 2020-04-05 | 2021-12-15 | Pfizer | Compuestos y metodos para el tratamiento de covid-19. |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| EP4489748A1 (en) * | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| CA3254546A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
| CN119156211A (zh) * | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| US20250353832A1 (en) * | 2022-10-12 | 2025-11-20 | Adama Makhteshim Ltd. | Process for the preparation of aminopyridazine derivatives |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6420415B1 (en) | 1998-09-21 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Thiol compounds, their production and use |
| JP2000159747A (ja) | 1998-09-21 | 2000-06-13 | Takeda Chem Ind Ltd | 新規チオ―ル誘導体、その製造法および用途 |
| IT1303737B1 (it) | 1998-11-11 | 2001-02-23 | Smithkline Beecham Spa | Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1. |
| PT2208727E (pt) | 2002-09-19 | 2012-10-11 | Lilly Co Eli | Éteres diarílicos como antagonista do receptor opióide |
| US7365209B2 (en) | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
| EP1606275B1 (en) | 2003-03-07 | 2008-08-27 | Eli Lilly And Company | Opioid receptor antagonists |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| EP1849835B1 (en) | 2005-02-18 | 2017-08-30 | Nippon Soda Co., Ltd. | Organic-inorganic composite body |
| RU2008140144A (ru) | 2006-03-10 | 2010-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента |
| PL2001456T3 (pl) | 2006-04-04 | 2010-05-31 | Emodys Gmbh | Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych |
| US7709522B2 (en) | 2008-01-22 | 2010-05-04 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| CR11559A (es) | 2008-03-25 | 2010-10-20 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| US8048895B2 (en) | 2008-04-18 | 2011-11-01 | Research Triangle Institute | Kappa opioid receptor ligands |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| EP2379524A1 (en) | 2008-12-18 | 2011-10-26 | Boehringer Ingelheim International GmbH | Serotonin 5-ht2b receptor inhibitors |
| HN2010001319A (es) | 2009-01-26 | 2013-01-15 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| WO2013059648A1 (en) | 2011-10-21 | 2013-04-25 | Neurotherapeutics Pharma, Inc. | 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use |
| EP2903966A1 (en) | 2012-10-02 | 2015-08-12 | Merck Patent GmbH | Pyrrolidines |
| WO2015109080A1 (en) | 2014-01-15 | 2015-07-23 | Research Triangle Institute | Kappa-opioid receptor selective opioid receptor antagonists |
| US10118896B2 (en) | 2014-11-26 | 2018-11-06 | University Of Kansas | Antagonists of the kappa opioid receptor |
-
2017
- 2017-11-22 US US15/820,679 patent/US10316021B2/en active Active
- 2017-11-27 HR HRP20230518TT patent/HRP20230518T1/hr unknown
- 2017-11-27 EP EP17818281.2A patent/EP3544972B8/en active Active
- 2017-11-27 PL PL17818281.2T patent/PL3544972T3/pl unknown
- 2017-11-27 CN CN201780084763.0A patent/CN110234638B/zh active Active
- 2017-11-27 AU AU2017365123A patent/AU2017365123B2/en active Active
- 2017-11-27 PT PT178182812T patent/PT3544972T/pt unknown
- 2017-11-27 ES ES17818281T patent/ES2947293T3/es active Active
- 2017-11-27 TW TW106141134A patent/TWI720272B/zh active
- 2017-11-27 RS RS20230453A patent/RS64258B1/sr unknown
- 2017-11-27 WO PCT/IB2017/057418 patent/WO2018096510A1/en not_active Ceased
- 2017-11-27 HU HUE17818281A patent/HUE061945T2/hu unknown
- 2017-11-27 MX MX2019006220A patent/MX389806B/es unknown
- 2017-11-27 FI FIEP17818281.2T patent/FI3544972T3/fi active
- 2017-11-27 DK DK17818281.2T patent/DK3544972T3/da active
- 2017-11-27 JP JP2019528746A patent/JP7051853B2/ja active Active
-
2019
- 2019-05-28 IL IL266962A patent/IL266962B/en unknown
- 2019-05-28 PH PH12019501172A patent/PH12019501172A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180148432A1 (en) | 2018-05-31 |
| TW201831460A (zh) | 2018-09-01 |
| TWI720272B (zh) | 2021-03-01 |
| EP3544972B8 (en) | 2023-06-07 |
| CN110234638B (zh) | 2022-10-21 |
| EP3544972B1 (en) | 2023-04-26 |
| AU2017365123B2 (en) | 2022-02-17 |
| ES2947293T3 (es) | 2023-08-04 |
| JP7051853B2 (ja) | 2022-04-11 |
| JP2019535799A (ja) | 2019-12-12 |
| MX2019006220A (es) | 2019-10-07 |
| CN110234638A (zh) | 2019-09-13 |
| MX389806B (es) | 2025-03-20 |
| US10316021B2 (en) | 2019-06-11 |
| IL266962A (en) | 2019-07-31 |
| FI3544972T3 (fi) | 2023-06-02 |
| CA3045242A1 (en) | 2018-05-31 |
| NZ754862A (en) | 2024-11-29 |
| IL266962B (en) | 2022-02-01 |
| PH12019501172A1 (en) | 2019-12-11 |
| AU2017365123A1 (en) | 2019-07-11 |
| DK3544972T3 (da) | 2023-05-30 |
| PL3544972T3 (pl) | 2023-07-24 |
| PT3544972T (pt) | 2023-06-20 |
| HUE061945T2 (hu) | 2023-09-28 |
| HRP20230518T1 (hr) | 2023-08-04 |
| WO2018096510A1 (en) | 2018-05-31 |
| EP3544972A1 (en) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017365123B2 (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
| KR102161364B1 (ko) | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 | |
| US9388192B2 (en) | Benzimidazole derivatives as Kinase Inhibitors | |
| JP2015157826A (ja) | 内臓痛を治療するためのインドール化合物および方法 | |
| CA3045816A1 (en) | Oga inhibitor compounds | |
| EA030085B1 (ru) | 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ | |
| US11390623B2 (en) | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | |
| JP2022070895A (ja) | ニューロキニン－１受容体アンタゴニストとしての化合物およびその使用 | |
| US20170066753A1 (en) | Oxadiazine compounds and methods of use thereof | |
| US20080081833A1 (en) | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | |
| CN104337812B (zh) | 取代的杂芳基化合物及其使用方法和用途 | |
| TWI675826B (zh) | 環狀經取代之咪唑并［４，５－ｃ］喹啉衍生物 | |
| US20210300943A1 (en) | Oga inhibitor compounds | |
| CA3045242C (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
| HK40014240B (zh) | 杂芳基苯氧基苯甲酰胺kappa阿片类配体 | |
| HK40014240A (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
| US20070197609A1 (en) | Salts of inducible nitric oxide synthase dimerization inhibitors | |
| JP7713954B2 (ja) | 核内受容体に対して活性な化合物 | |
| US20260125359A1 (en) | Heteroaryl compounds as multi-target protein kinase inhibitors | |
| TW202014191A (zh) | 具有選擇性ｂａｃｅ１抑制活性的四氫哌喃并衍生物 |